Swiss Rockets obtained an exclusive license to MGI/Complete Genomics’ CoolMPS sequencing chemistry for global commercialization outside the Asia‑Pacific region and announced plans to launch CoolMPS‑based sequencers as early as next year. Swiss Rockets will partner with Complete Genomics and MGI for manufacturing and R&D support while positioning the deal as an entry into next‑generation sequencing instrument markets dominated by established players. The company says its Swiss identity and perceived neutrality could help market CoolMPS in Europe and the U.S., where geopolitical tensions have complicated Chinese vendors’ expansion. The license grants perpetual rights outside Asia‑Pacific and an option to expand to Asia‑Pacific in 2026, subject to MGI decisions. Market observers note the move adds another instrument vendor to the crowded NGS landscape and could increase competition on chemistry and cost. Success will depend on instrument performance, supply chain execution, regulatory clearances, and adoption by academic and clinical customers.